CRISPR and CAS Gene Market to Surpass US$ 7,603.8 Million by 2026

CRISPR technology is a simple yet powerful nucleic acid-targeting editing tools for genome. It allows researchers to easily alter DNA sequences and modify gene function. It has many potential applications, which include correcting genetic defects, treating and preventing the spread of diseases, and improving crops. It is faster, cheaper, and more accurate than previous techniques of editing DNA like ZFNs (Zinc Finger Nucleases) and TALENs (Transcription Activator-Like Effector Nucleases). And has a wide range of potential applications. Researchers are focusing on its use in animal models or isolated human cells, with the aim to eventually use the technology for routinely treating diseases in humans.

Read report Overview @ https://www.coherentmarketinsights.com/market-insight/crispr-and-cas-gene-market-2598

Increasing research & development and demand for clinical trials for development of new technologies in CRISPR and CAS gene therapy for treatment of cancer is one of the major driving factor. For instance, The Parker Institute for Cancer Immunotherapy, a non-profit organization formed in April 2016, with a US$ 250 million grant from the Parker Foundation, agreed to sponsor the first in-human clinical trials of CRISPR-enabled technology targeting three types of cancer. The trial, led by the University of Pennsylvania, will use CRISPR-modified T-cells, a part of the human immune system, to treat myeloma, melanoma, and sarcoma. The trial was commenced in 2017.

Therefore, increasing research on CRISPR and CAS gene market is expected to create a favorable environment for CRISPR and CAS gene market growth in the near future.

Request PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2598

The global CRISPR and CAS Gene market is expected to expand at a CAGR of 20.8% during the forecast period (2018–2026), owing to increasing research & development and demand for research.

Among product type, segment vector-based Cas is expected to hold major revenue share in 2026. Various companies are focusing on collaborations to conduct research and development for treatment of various diseases such as cancer, AIDS, genetic diseases, others, which in turn is expected to drive growth of this segment in the market. For instance, August 2016, CRISPR Therapeutics and pharmaceutical company Bayer AG founded Casebia Therapeutics, a joint research venture to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease.

Free Sample Report + All Related Graphs & Charts @ https://www.coherentmarketinsights.com/insight/request-sample/2598 

Major players operating in the global CRISPR and CAS Gene market include Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.

Detailed Segmentation:

Global CRISPR and CAS Gene Market, By Product Type:
Vector-based Cas
DNA-free Cas
Global CRISPR and CAS Gene Market, By Application:
Genome Engineering
Disease models
Functional Genomics
Knockdown/activation
Other Applications

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.